July 2026 Research Update

This month, research on cholesteatoma surgery mainly focused on comparing different operative approaches (including endoscopic vs microscopic routes and different mastoid surgery styles) and describing how these choices may affect hearing, recovery experience, and recurrence. The strongest long-term evidence is still being built, because one large randomized trial is in progress to compare a common operation with versus without added cavity filling, with planned five-year follow-up. [1]

In adults undergoing tympano-mastoidectomy for chronic ear disease with or without cholesteatoma, intact bridge mastoidectomy had hearing improvement that fell between intact canal wall surgery and open cavity surgery, while eardrum graft success was high in all groups. Hearing gain was 11.1 dB HL with intact canal wall surgery, 6.1 dB HL with intact bridge mastoidectomy, and 0.1 dB HL with open cavity surgery. [2]

In children with chronic suppurative otitis media with cholesteatoma, an endoscopic transcanal approach was linked to less short-term postoperative pain and higher quality-of-life scores at one month than a microscopic behind-the-ear approach in a non-randomized comparison. The report also described age-related differences, with physical functioning dipping in adolescents and emotional functioning worsening with age. [3]

For extensive mastoid cholesteatoma, a small single-center series described total transcanal endoscopic modified radical mastoidectomy as technically feasible in selected patients, but recurrence and nerve-related symptoms still occurred. Two cases had delayed facial nerve weakness that fully resolved, and 2 cases needed revision surgery through a behind-the-ear mastoidectomy approach because of recurrence. [4]

Two pediatric reports described more specialized operations used in particular situations. In a 20-child series of subtotal petrosectomy, major complications occurred in 2 of 20 children, including a recurrence that needed revision surgery and conversion to an open technique, while no permanent facial nerve palsy was reported. [5]

A single case report described a rare cholesteatoma in the frontal sinus in a child and reported successful surgical treatment using osteoplastic obliteration, while noting there is not a clear consensus on the best access route or whether to obliterate for this location. Because it is one patient, it may not apply to most cholesteatoma care. [6]

For patients and caregivers, these studies highlight that "cholesteatoma surgery" is not one single operation, and the approach may affect different outcomes, such as hearing changes, early recovery pain, and the chance of cholesteatoma coming back. Some results come from small or retrospective studies, so uncertainty remains about how well they generalize and how they compare over many years. A large randomized study designed to measure five-year recurrence, hearing, quality of life, and costs may help clarify the long-term differences between common techniques (with and without mastoid cavity obliteration), but results were not yet available this month. [1]

Taken together, these studies suggest that hearing outcomes in chronic ear disease are influenced by the overall history and activity of the condition (such as how long it has been present and how often the ear drains), not just whether cholesteatoma is present. They also show that combining hearing tests and clinical details with information from a CT scan may improve predictions of hearing after surgery, but this approach is still under development. [7] [8] [9]

In a retrospective study of 62 people with chronic suppurative otitis media (a long-lasting, draining middle ear infection), hearing test results were similar whether or not cholesteatoma was present. Instead, older age and a longer disease duration were the factors that independently predicted having mixed hearing loss (both conductive and inner-ear components). [7]

In a retrospective pediatric surgery study of 60 ears, more frequent episodes of ear drainage (otorrhea) were linked to greater worsening in bone-conduction thresholds, which reflects inner-ear hearing. Five or more drainage episodes was the cutoff that best predicted a clinically meaningful worsening of at least 10 dB, while the type of bacteria cultured (non-skin germs versus no growth/normal flora) did not change the hearing outcome in this analysis. [8]

One single-center model-development study tested computer prediction models that combine temporal bone CT scan information with clinical variables to estimate postoperative hearing after cholesteatoma surgery. The best-performing model (a gated approach that adds image information conservatively) reduced average prediction error for postoperative air-conduction hearing compared with using clinical variables alone, but the authors noted it needs external validation before it could be considered for clinical use. [9]

For patients and caregivers, this research mainly adds context about why hearing outcomes can vary: studies point toward factors like chronicity and how often the ear is actively draining as being linked to inner-ear hearing changes, while cholesteatoma presence alone did not explain differences in hearing in one cohort. CT-based prediction tools may eventually help set expectations after surgery, but right now the evidence is from single-center, retrospective work and the models still need testing in other hospitals and patient groups. [7] [8] [9]

Overall, the research shows that taste disturbance can happen after middle ear surgery and is closely linked to how much the chorda tympani nerve (a taste-related nerve running through the middle ear) is stretched, injured, or cut. Taste changes often lessen with time, but recovery can be slower and incomplete when the nerve is more severely injured, and persistent symptoms may affect daily life. [10]

In a systematic review and meta-analysis, endoscopic middle ear surgery had fewer early taste problems than microscopic techniques. This suggests the way the surgeon reaches the middle ear can influence short-term taste symptoms. [10]

The same analysis found that preserving the chorda tympani nerve markedly reduced the risk of postoperative taste disturbance compared with cutting it, and milder nerve handling was linked to better recovery over time. Taste disturbance commonly decreased from the early period after surgery to lower levels beyond 12 months, but more severe nerve injury showed slower and less complete improvement. [10]

When taste disturbance persisted, patients reported lower oral satisfaction and worse health-related quality of life, highlighting that even a non-life-threatening symptom can still meaningfully affect everyday well-being. [10]

For patients and caregivers, these results help explain why taste can change after cholesteatoma or other middle ear operations: the taste nerve may be irritated, stretched, or damaged during surgery. The evidence here is based on a synthesis of multiple studies, supporting the general pattern that many taste changes improve over time, while a smaller group has longer-lasting effects that can reduce enjoyment of food and overall quality of life; exactly who will have persistent symptoms remains uncertain. [10]

Across these reports, cholesteatoma was sometimes not recognized at first, and in other situations the opposite happened: a different condition was mistaken for cholesteatoma. A repeated pattern was that symptoms like ear drainage, pain, dizziness, or hearing loss were not specific, so imaging and (when tissue was removed) careful pathology review were key to sorting out what was going on. [11] [12] [13] [14]

One case report described a 4-year-old boy with persistent one-sided ear drainage who had multiple ear, nose, and throat evaluations without a cholesteatoma diagnosis until a high-resolution CT scan suggested cholesteatoma with bony erosion. Surgery then confirmed cholesteatoma and found partial hearing-bone damage, showing how a delay can happen even when symptoms continue. [11]

Another case report described a 64-year-old man diagnosed with a very large recurrent cholesteatoma with extension inside the skull, presenting with severe ear pain and dizziness, 45 years after his last ear surgery. The authors emphasized that leftover disease may remain quiet for long periods before becoming obvious. [12]

Misdiagnosis can also go in the other direction. In a case report of an elderly man, an external ear canal lesion looked like cholesteatoma on exam and CT imaging, and early biopsies suggested cholesteatoma, but the final diagnosis after extensive sampling was a benign trichoepithelioma (a skin tumor). This illustrates how limited tissue sampling can miss less common conditions and why the final pathology report may change the diagnosis. [13]

In a retrospective series of 11 patients with middle ear adenomatous neuroendocrine tumors (MEANTs), 5 were thought to have cholesteatoma before surgery. All patients had hearing loss, and many also had tinnitus or a feeling of fullness, which overlaps with symptoms people may associate with cholesteatoma; the diagnosis was confirmed after surgery using pathology and special lab staining of the tissue. [14]

For patients and caregivers, this set of studies mainly provides background on why cholesteatoma can be missed or confused with other ear conditions: symptoms often overlap, and the label may change once imaging and detailed tissue examination are available. The strongest evidence here comes from individual case reports and a small case series, so it cannot estimate how often these situations occur, but it helps explain how diagnostic uncertainty can happen in real-world care. [11] [12] [13] [14]

Across these papers, infection stands out as a key driver of complications in cholesteatoma, especially when it spreads beyond the ear. At the same time, lab testing suggests many cholesteatoma-related bacteria can form biofilms, but it is still unclear whether stronger biofilms translate into worse disease or higher risk of complications. [15] [16]

One case report described a 33-year-old woman who developed Lemierre syndrome after tympanoplasty for cholesteatoma, including septic thrombosis and progression to septic shock. Complications included hemorrhagic rupture of a thrombotic lateral sinus, acute respiratory distress, and septic pulmonary emboli, and care required intensive care, revision surgery, antibiotics, and anticoagulation. The authors noted that anticoagulation in this setting remains debated because evidence for benefit is limited. [15]

In a cross-sectional study of 49 people with chronic suppurative otitis media (long-lasting draining ear infection) with cholesteatoma undergoing mastoidectomy, bacteria grown from cholesteatoma tissue showed biofilm formation in all isolates. Most biofilm formation was labeled weak in the lab test, and Pseudomonas aeruginosa was the most common species found; however, biofilm strength did not show a clear relationship with a clinical severity grading system in this sample. The authors emphasized the need for larger studies to clarify whether biofilms meaningfully drive severity or outcomes in real-world disease. [16]

For patients and caregivers, these papers mainly add background about why cholesteatoma can sometimes lead to serious complications: infection can extend beyond the ear and, rarely, become life-threatening, as shown in a single-patient report. The biofilm study supports the idea that cholesteatoma-related bacteria often have features that can help them persist, but it did not show that stronger biofilms meant more severe disease, so the role of biofilms in predicting complications or recurrence remains uncertain.

Across the included research, the key message is that the tissue lining of cerebellopontine angle epidermoid cysts shows a pattern of cell proteins typical of stratified squamous (skin-like) epithelium, supporting an ectoderm (outer-layer) developmental origin. In this dataset, the same tissue markers did not clearly separate cases that later needed another operation or showed malignant transformation, so their role as predictors remains uncertain. [17]

When researchers stained 26 samples from 23 patients for cytokeratins (structural proteins that help identify epithelial cell types), cytokeratin 14 was strongly positive in all samples, while cytokeratin 7 and cytokeratin 8 varied across samples. Cytokeratin 19 was moderate to strong in most samples, and cytokeratin 20 was usually negative, a pattern interpreted as consistent with stratified squamous epithelium rather than other epithelial types. [17]

The study also measured Ki67, a marker linked to how quickly cells are dividing, and reported higher values in the malignant tumors than in the benign cysts, but the cytokeratin patterns did not differ between benign and malignant cases. Ki67 also did not differ between people who did or did not undergo reoperation, suggesting these markers were not useful for predicting these outcomes in this small retrospective cohort. The authors noted that this cytokeratin profile differed from that of middle ear cholesteatoma. [17]

This group of results is mainly background biology: it helps describe what kinds of cells are present in cerebellopontine angle epidermoid cysts and how they may differ from middle ear cholesteatoma at the tissue-marker level. For patients, the immediate takeaway is that, in this small study, these lab markers did not reliably indicate who would need another operation or who might develop malignant change, so they are not yet established as practical predictors. More research in larger groups and across different locations would be needed to know whether any tissue markers can consistently guide risk assessment.

Across this research, a consistent pattern was that ear surgery complexity is not one-size-fits-all (in this mixed group of operations, about half were for cholesteatoma): operative time varied in predictable ways based on the planned approach and the specific parts of the operation performed. The evidence comes from a single-hospital review, so it suggests a useful direction but does not prove how well this works in every setting. [18]

In a retrospective cohort of 300 tympanomastoid surgeries, the SAMEO-ATO classification (a structured way to label key elements of ear surgery) showed clear differences in average operating time across its subgroups. For example, a retroauricular (behind-the-ear) approach took longer on average than an endaural (through-the-ear-canal) approach (119.2 vs 61.1 minutes). [18]

More extensive surgical steps also tended to take longer than simpler ones. Cases labeled with no mastoidectomy were among the shortest on average (92.4 minutes), while some more involved mastoid-related subgroups were much longer (for example, one subgroup averaged 180.7 minutes). [18]

The authors noted important uncertainties that affect how confidently time can be used as a stand-in for surgical complexity, including missing information on surgeon experience and limited preoperative detail about disease extent. They also raised concerns about ambiguities within parts of the classification and how easily it translates to other classification systems or hospitals. [18]

For patients and caregivers, this work mainly matters as background on why two people with cholesteatoma may have very different-looking operations and time in the operating room, even when the diagnosis is the same. A structured way of labeling what is planned and what is done during surgery may help teams communicate about expected complexity, but it is still uncertain how well these time-based estimates apply across surgeons and centers, or how closely they reflect recovery, hearing results, or long-term control of cholesteatoma.